Deep Science Ventures and General Inception collaborate to create fibrosis-focused therapeutics company

  • 📰 NewsMedical
  • ⏱ Reading Time:
  • 80 sec. here
  • 5 min. at publisher
  • 📊 Quality Score:
  • News: 42%
  • Publisher: 71%

Fibrosis Nachrichten

Therapeutics,Technology

Deep Science Ventures, a UK-based venture studio, and General Inception, a US-based venture studio, today announced a collaboration to create a company focused on developing novel treatments for fibrosis.

Deep Science VenturesDec 12 2024 Widely recognized as an area of significant unmet need, Deep Science Ventures and General Inception’s European arm, Igniter Europe, aim to establish a company dedicated to overcoming current bottlenecks in fibrosis therapeutics by developing a novel concept and taking it through to full company launch.

Deep Science Ventures and General Inception each have a strong track record in scientific discovery and venture creation. Together they will apply a new start-up strategy that combines Deep Science Ventures’ first-principles driven inventive methodology and AI toolset with General Inception’s record of progressing early-stage innovations.

Deep Science Ventures has built and launched over 40 companies harnessing scientific invention to solve major world challenges, combining interdisciplinary expertise to develop solutions in fields such as therapeutics, climate, restorative agriculture and computation. Deep Science Ventures’ methodology focuses on iteratively profiling the techno-economic requirements and generating matched candidate solutions.

General Inception provides strategic support, capital, and resources through its venture studio, which has built a portfolio of 45 companies across therapeutics, synthetic biology and life science tools and diagnostics. Igniter Europe, General Inception’s European arm, focuses on the growth of high-potential European ventures, particularly in therapeutics and life sciences tools and technology sectors.

We are pleased to partner with General Inception to address the critical unmet need in fibrosis and the need for more impactful treatments. Our approach, driven by medical need rather than technology-led solutions, leverages the complementary strengths of our two venture studios. Together, we will develop an approach to tackle fibrosis, and we are excited to see the impact this will have on patients.

Wir haben diese Nachrichten zusammengefasst, damit Sie sie schnell lesen können. Wenn Sie sich für die Nachrichten interessieren, können Sie den vollständigen Text hier lesen. Weiterlesen:

 /  🏆 19. in AT
 

Vielen Dank für Ihren Kommentar.Ihr Kommentar wird nach Prüfung veröffentlicht.

Österreich Neuesten Nachrichten, Österreich Schlagzeilen

Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.

Gareth Bale huge net worth, family life, Rory McIlroy bond, golf journey and business venturesGareth Bale will be in the TNT Sports studio for the Champions League quarter-final between Liverpool and Real Madrid at Anfield
Herkunft: EchoWhatsOn - 🏆 74. / 59 Weiterlesen »

French oil major TotalEnergies suspends fresh investment in Adani joint venturesIndian conglomerate releases report on operations after US indictment of founder Gautam Adani for alleged bribery
Herkunft: ftenergy - 🏆 47. / 63 Weiterlesen »